Results 81 to 90 of about 427,029 (392)

Clinical Implication of Targeting of Cancer Stem Cells [PDF]

, 2012
The existence of cancer stem cells (CSCs) is receiving increasing interest particularly due to its potential ability to enter clinical routine. Rapid advances in the CSC field have provided evidence for the development of more reliable anticancer ...
Al-Hajj M, Bao S, Bardsley MR, Barlogie B, Bentzen SM, Bertout JA, Blazek ER, Bruns CJ, Brunsvig PF, C.J. Bruns, Cao X, Chen MS, Clayton S, Collins AT, Cortes J, Costello R, Dalerba P, Diehn M, Dou J, Dylla SJ, Eyler CE, Fischer S, Garvalov BK, Ghiaur G, Gibbs CP, Gilbert CA, H. Niess, Haferlach T, Hochhaus A, Hosen N, Huff CA, Hurwitz H, Jiang X, Jones RJ, Jones RJ, Jones RJ, Ju Z, K.-W. Jauch, Kanamori M, Kiladjian JJ, Klonisch T, Kojima T, Korpal M, L. Zhao, Li C, Liu G, Liu R, Liu S, Lonardo E, Mauro MJ, McDermott SP, Merante S, Mimeault M, Moserle L, O’Brien SG, Park CY, Phillips TM, Platet N, Q. Bao, Rasheed ZA, Reya T, Reya T, Richardson GD, Roeder I, Seidel S, Singh A, Singh SK, Strojnik T, Stupp R, Suh MR, Szotek PP, Tang C, Tang M, Todaro M, Tu LC, Vermeulen L, Wilson BJ, Wright MH, Xu N, Y. Zhao, Yu F, Zhao C, Zhou BB   +82 more
core   +1 more source

Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.

Journal of Clinical Oncology, 2016
PURPOSE A dramatic improvement in the survival of patients with chronic myeloid leukemia (CML) occurred after the introduction of imatinib mesylate, the first tyrosine kinase inhibitor (TKI).
H. Bower, M. Björkholm, P. Dickman, M. Höglund, P. Lambert, T. Andersson   +5 more
semanticscholar   +1 more source

Neuropsychiatric Symptoms Mimicking Dementia in a Patient Treated With Imatinib

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Tyrosine kinase inhibitors are the cornerstone of chronic myeloid leukemia treatment. Newer agents have more potency and a broader spectrum of action, but also a higher potential for neuropsychiatric side effects. We present a case of a patient on imatinib who developed progressive cognitive, mood, and behavioral alterations.
Ashley Jones, Samuele Bonomi, Keith E. Stockerl‐Goldstein, Randall J. Bateman   +3 more
wiley   +1 more source

Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells

Haematologica, 2010
Background Tyrosine kinase inhibitors, such as imatinib, are not considered curative for chronic myeloid leukemia – regardless of the significant reduction of disease burden during treatment – since they do not affect the leukemic stem cells.
Tom Lenaerts, Jorge M. Pacheco, Arne Traulsen, David Dingli   +3 more
doaj   +1 more source

A rare case of melanosis of the hard palate mucosa in a patient with chronic myeloid leukemia [PDF]

, 2015
Imatinib Mesylate, also known as Gleevec or ST1-571, is a tyrosine-kinase inhibitor used as the gold standard medication for the chronic myeloid leukemia (CML); Imatinib has indeed deeply revolutionized the CML therapy allowing most patients to have a ...
Bosco, Daniela, Fantozzi, Paolo Junior, Palaia, Gaspare, Romeo, Umberto, Tenore, Gianluca   +4 more
core   +3 more sources

Immune‐Driven Expression in Inclusion Body Myositis With T‐Cell Large Granular Lymphocytic Leukemia

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives T‐cell large granular lymphocytic leukemia (T‐LGLL), reported in up to 58% of inclusion body myositis (IBM) patients, is a rare leukemia of cytotoxic or less commonly helper T cells. The range of myopathies in T‐LGLL and the impact of coexisting T‐LGLL in IBM are not well understood. Our objectives are to investigate the spectrum of
Pannathat Soontrapa, Iago Pinal‐Fernandez, Pritikanta Paul, Michael P. Skolka, Margherita Milone, Min Shi, Mithun V. Shah, Maria Casal‐Dominguez, Katherine Pak, Andrew L. Mammen, Teerin Liewluck   +10 more
wiley   +1 more source

Clonal karyotype evolution involving ring chromosome 1 with myelodysplastic syndrome subtype RAEB-t progressing into acute leukemia [PDF]

, 2006
s Karyotypic evolution is a well-known phenomenon in patients with malignant hernatological disorders during disease progression. We describe a 50-year-old male patient who had originally presented with pancytopenia in October 1992.
Bennett JM, Bettina Wunderlich, Brigitte Poleck-Dehlin, Chen Z, Christoph Schmid, Cutler CS, De Witte T, Depil S, Georg Ledderose, Gisselsson D, Gullingsrud EO, Hans Jochen Kolb, Hebart H, Helga Schmetzer, Hoffmann WK, Hoffmeister PA, Holler E, Johann Mittermüller, Johansson B, Jotterand M, Kern W, Kolb HJ, Kolb HJ, Massenkeil G, Mattano, Mhawesch P, Mittermuller J, Moss PA, Mufti GJ, Rothe G, Sanders JE, Schmetzer H, Schmetzer H, Schmetzer HM, Schmid C, Seabright M, Seber A, Slovak ML, Sole F, Sole F, Thomas Duell, Tichelli A, Tichelli A, van Esser JW, Xu J, Yan J, Yoshida A   +46 more
core   +1 more source

Evaluation of the Dual Impact of Nanotechnologies on Health and Environment Through Alternative Bridging Models

Advanced Healthcare Materials, EarlyView.
This review explores how alternative invertebrate and small‐vertebrate models advance the evaluation of nanomaterials across medicine and environmental science. By bridging cellular and organismal levels, these models enable integrated assessment of toxicity, biodistribution, and therapeutic performance.
Marie Celine Lefevre, Margherita Bernardeschi, Matteo Battaglini, Gianni Ciofani   +3 more
wiley   +1 more source

Role of the bone morphogenic protein pathway in developmental haemopoiesis and leukaemogenesis [PDF]

, 2016
Myeloid leukaemias share the common characteristics of being stem cell-derived clonal diseases, characterised by excessive proliferation of one or more myeloid lineage.
Toofan, Parto, Wheadon, Helen
core   +1 more source

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

Leukemia, 2017
The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission (TFR; i.e., the ability to maintain a molecular response after stopping therapy) following frontline nilotinib treatment. Patients with Philadelphia chromosome-
A. Hochhaus, T. Masszi, F. Giles, J. Radich, D. Ross, M. T. G. Casares, A. Hellmann, J. Stentoft, E. Conneally, V. García‐Gutiérrez, N. Gattermann, W. Wiktor-Jedrzejczak, P. Coutre, B. Martino, Susanne Saussele, H. Menssen, W. Deng, N. Krunic, V. Bédoucha, G. Saglio   +19 more
semanticscholar   +1 more source